© 2022 MJH Life Sciences and Drug Topics. All rights reserved.
© 2022 MJH Life Sciences™ and Drug Topics. All rights reserved.
May 11, 2020
In July 2019, the FDA approved darolutamide (Nubeqa, Bayer) for men with prostate cancer that has not spread (ie, nonmetastatic) and no longer responds to medical or surgical treatment that lowers testosterone (ie androgen deprivation therapy).